Transitional Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: TRN018 MIFTS: 51	Transitional Cell Carcinoma Categories: Cancer diseases, Nephrological diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Transitional Cell Carcinoma

MalaCards integrated aliases for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma ¹¹ ¹⁹ ⁷⁵ ¹⁴ ¹⁶

Carcinoma, Transitional Cell ⁴³ ⁷¹

Transitional Cell Neoplasm ¹¹ ⁷¹

Transitional Cell Carcinoma of Bladder ⁷¹

Carcinoma Transitional Cell ⁵³

Urothelial Cell Carcinoma ¹¹

Transitional Cell Tumor ¹¹

Transitional Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Nephrological diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:2671

MeSH ⁴³ D002295

NCIt ⁴⁹ C2930 C6783

SNOMED-CT ⁶⁸ 118287003 27090000

EFO ¹⁶ EFO_1000601

UMLS ⁷¹ C0007138 C0279680 C0334265

Sources

Summaries for Transitional Cell Carcinoma

GARD: ¹⁹ A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.

MalaCards based summary: Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to bladder urothelial carcinoma and sarcomatoid transitional cell carcinoma. An important gene associated with Transitional Cell Carcinoma is UPK2 (Uroplakin 2), and among its related pathways/superpathways are DNA Damage and Endometrial cancer. The drugs Cholecalciferol and Calciferol have been mentioned in the context of this disorder. Affiliated tissues include lymph node, prostate and kidney, and related phenotypes are neoplasm and homeostasis/metabolism

Disease Ontology: ¹¹ A carcinoma that derives from transitional epithelial cells.

Wikipedia: ⁷⁵ Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs... more...

Sources

Related Diseases for Transitional Cell Carcinoma

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 810)

#	Related Disease	Score	Top Affiliating Genes
1	bladder urothelial carcinoma	33.4	TP53 MKI67 KRT20 FGFR3 ERBB2 CDH1
2	sarcomatoid transitional cell carcinoma	33.2	FGFR3 CDH1
3	urethra transitional cell carcinoma	33.0	UPK3A TP53 EGFR
4	papillary transitional carcinoma	32.9	UPK3A TP53 KRT7 KRT20 BRINP1
5	endometrial transitional cell carcinoma	32.9	KRT7 KRT20
6	bladder papillary transitional cell neoplasm	32.3	UPK3A TP53 KRT7 KRT20 FGFR3 BRINP1
7	fallopian tube carcinoma	32.2	TP53 MSH2 KRT7 ERBB2
8	urinary tract papillary transitional cell benign neoplasm	32.0	UPK3A TP53 KRT7 KRT20 FGFR3 BRINP1
9	prostate cancer	31.9	TP63 TP53 PTGS2 PSCA MSH2 MKI67
10	hydronephrosis	31.7	UPK3A UPK2 UPK1B KRT7
11	bladder cancer	31.6	UPK3A UPK2 UPK1A TP63 TP53 PTGS2
12	inverted papilloma	31.5	TP53 MKI67 KRT20
13	cystitis	31.5	UPK3A UPK1A TP53 PTGS2 KRT7 KRT20
14	renal cell carcinoma, nonpapillary	31.4	TP53 MKI67 KRT7 KRT20 KRT18 IFNA2
15	suppression of tumorigenicity 12	31.4	TP53 ERBB2 EGFR CDH1
16	ureteral benign neoplasm	31.3	UPK3A TP53 KRT7 KRT20 FGFR3
17	papilloma	31.3	TP63 TP53 PTGS2 KRT7 KRT20 FGFR3
18	small cell carcinoma	31.3	TP53 KRT7 KRT20 EGFR
19	urinary tract obstruction	31.2	UPK3A KRT7 CDH1
20	renal cell carcinoma, papillary, 1	31.2	TP53 KRT7 FGFR3 ERBB2 EGFR CDH1
21	appendix adenocarcinoma	31.2	TP53 KRT7 KRT20
22	papillary carcinoma	31.2	TP63 MKI67 KRT7 KRT20 ERBB2 CDH1
23	paget disease, extramammary	31.2	KRT7 KRT20 ERBB2
24	mammary paget's disease	31.1	KRT7 KRT20 ERBB2
25	serous cystadenocarcinoma	31.1	TP53 MSH2 KRT7 ERBB2 CDH1
26	nephrogenic adenoma	31.1	UPK3A KRT7
27	vesicoureteral reflux	31.1	UPK3A UPK2 UPK1B UPK1A
28	carcinosarcoma	31.0	TP53 KRT7 ERBB2 EGFR CDH1
29	squamous cell carcinoma	31.0	TP63 TP53 PTGS2 MKI67 KRT7 FGFR3
30	ureter, cancer of	31.0	MSH2 KRT7 FGFR3
31	human papillomavirus infectious disease	31.0	TP53 ERBB2 EGFR
32	vaginal cancer	31.0	TP53 KRT7 EGFR
33	adenocarcinoma	31.0	TP53 PTGS2 MSH2 KRT7 KRT20 FGFR3
34	small cell cancer of the lung	30.9	TP53 KRT7 KRT20 KRT18 EGFR
35	diarrhea	30.9	IFNA2 ERBB2 EGFR CDH1
36	colon adenocarcinoma	30.9	TP53 PTGS2 MKI67 KRT20 EGFR CDH1
37	peripheral nervous system disease	30.9	TP53 PTGS2 ERBB2 EGFR CDH1
38	interstitial cystitis	30.9	UPK3A UPK2 UPK1B UPK1A
39	lynch syndrome	30.9	TP53 PTGS2 MSH2 KRT7 ERBB2 EGFR
40	penile cancer	30.8	TP53 EGFR CDH1
41	urethral diverticulum	30.8	UPK3A KRT7 KRT20
42	wilms tumor 1	30.8	TP53 KRT7 ERBB2 EGFR CDH1
43	mucinous adenocarcinoma	30.7	TP53 MSH2 KRT7 KRT20 ERBB2 EGFR
44	papillary serous adenocarcinoma	30.7	TP53 KRT7 ERBB2
45	papillary adenocarcinoma	30.7	TP53 KRT7 ERBB2
46	vulval paget's disease	30.7	UPK3A KRT7 ERBB2
47	cervix carcinoma	30.7	TP53 KRT7 FGFR3 ERBB2 EGFR CDH1
48	urethral benign neoplasm	30.7	TP53 KRT7 KRT20
49	rectum cancer	30.7	TP53 MSH2 KRT20 EGFR
50	endometrial cancer	30.7	TP53 PTGS2 MSH2 MKI67 KRT7 KRT20

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:

Sources

Symptoms & Phenotypes for Transitional Cell Carcinoma

GenomeRNAi Phenotypes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.15	BRINP1 CDH1 EGFR ERBB2 FGFR3 IFNA2
2	no effect	GR00402-S-2	10.15	BRINP1 EGFR ERBB2 FGFR3 IFNA2 KRT18

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.2	CDH1 EGFR ERBB2 FGFR3 KRT18 MKI67
2	homeostasis/metabolism	MP:0005376	10.2	BRINP1 CDH1 EGFR ERBB2 FGFR3 KRT7
3	normal	MP:0002873	10.17	CDH1 EGFR ERBB2 FGFR3 IFNA2 MKI67
4	no phenotypic analysis	MP:0003012	10.01	BRINP1 CDH1 EGFR FGFR3 MKI67 PTGS2
5	renal/urinary system	MP:0005367	9.97	EGFR FGFR3 KRT7 PTGS2 TP53 TP63
6	cellular	MP:0005384	9.93	BRINP1 CDH1 EGFR ERBB2 FGFR3 KRT18
7	digestive/alimentary	MP:0005381	9.86	CDH1 EGFR ERBB2 FGFR3 MSH2 PTGS2
8	immune system	MP:0005387	9.73	CDH1 EGFR FGFR3 IFNA2 KRT18 MKI67
9	integument	MP:0010771	9.28	CDH1 EGFR ERBB2 FGFR3 MSH2 PSCA

Sources

Drugs & Therapeutics for Transitional Cell Carcinoma

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 4

67-97-0, 1406-16-2

5280795 10883523

Calciferol

Phase 4

Ramucirumab

Approved, Investigational

Phase 3

947687-13-0

Aminolevulinic acid

Approved

Phase 3

106-60-5

137

Panitumumab

Approved, Investigational

Phase 3

339177-26-3

Avelumab

Approved, Investigational

Phase 3

1537032-82-8

Topotecan

Approved, Investigational

Phase 2, Phase 3

123948-87-8, 119413-54-6

60699 60700

Infigratinib

Approved, Investigational

Phase 3

872511-34-7

53235510

Pembrolizumab

Approved

Phase 2, Phase 3

1374853-91-4

254741536

Lenvatinib

Approved, Investigational

Phase 2, Phase 3

417716-92-8

9823820

BCG vaccine

Approved, Investigational

Phase 3

Atezolizumab

Approved, Investigational

Phase 3

1380723-44-3

Gefitinib

Approved, Investigational

Phase 3

184475-35-2

123631

Ciprofloxacin

Approved, Investigational

Phase 3

85721-33-1, 93107-08-5

2764

Cephalexin

Approved, Investigational, Vet_approved

Phase 3

15686-71-2

27447

Valrubicin

Approved

Phase 3

56124-62-0

41744

Laevulinic Acid

Experimental

Phase 3

123-76-2

11579

Cediranib

Investigational

Phase 3

288383-20-0

9933475

Maleic acid

Experimental, Investigational

Phase 3

110-16-7, 110-17-8

444266 444972

Paclitaxel poliglumex

Experimental, Investigational

Phase 3

263351-82-2

Carotenoids

Phase 3

Hematinics

Phase 3

BB 1101

Phase 3

Photosensitizing Agents

Phase 3

topoisomerase I inhibitors

Phase 2, Phase 3

Taxane

Phase 3

108169

Anesthetics

Phase 3

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Immune Checkpoint Inhibitors

Phase 2, Phase 3

Liver Extracts

Phase 2, Phase 3

Protein Kinase Inhibitors

Phase 3

Adjuvants, Immunologic

Phase 3

Fluoroquinolones

Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 3

interferons

Phase 2, Phase 3

Benzocaine

Approved, Investigational

Phase 2

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 2

1401-55-4

16129878 16129778

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Hydroxocobalamin

Approved

Phase 2

13422-51-0

15589840 44475014

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Mecobalamin

Approved, Investigational

Phase 2

13422-55-4

Raloxifene

Approved, Investigational

Phase 2

82640-04-8, 84449-90-1

5035

Tamoxifen

Approved

Phase 2

10540-29-1, 54965-24-1

2733526

Ifosfamide

Approved

Phase 2

3778-73-2

3690

Miconazole

Approved, Investigational, Vet_approved

Phase 1, Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 1, Phase 2

23593-75-1

2812

Epirubicin

Approved

Phase 2

56420-45-2

41867

Arsenic trioxide

Approved, Investigational

Phase 2

1327-53-3

518740

Interventional clinical trials:

(show top 50) (show all 546)

#	Name	Status	NCT ID	Phase	Drugs
1	Pilot Study of the Biological Effects of Vitamin D in Patients With Resectable Urinary Tract Urothelial Carcinoma	Completed	NCT04197089	Phase 4	Vitamin D
2	A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma	Not yet recruiting	NCT05488353	Phase 4	Disitamab Vedotin for Injection,Penpulimab Injection
3	Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?	Unknown status	NCT00719303	Phase 3
4	A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium	Unknown status	NCT01830231	Phase 2, Phase 3	Cabazitaxel;Vinflunine
5	Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study	Unknown status	NCT00146276	Phase 3	gemcitabine
6	Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study -	Unknown status	NCT03296306	Phase 3	Treatment duration of cisplatin based chemotherapy
7	A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer	Unknown status	NCT01993979	Phase 3	Chemotherapy
8	A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression	Unknown status	NCT03193788	Phase 3	pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
9	A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	Completed	NCT00951496	Phase 3	Carboplatin;Cisplatin;Paclitaxel
10	A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3	Carboplatin;Paclitaxel
11	Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study	Completed	NCT00867347	Phase 3
12	A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy	Completed	NCT00389155	Phase 2, Phase 3	Vinflunine;Gemcitabine
13	Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy.	Completed	NCT01668459	Phase 2, Phase 3	Cabazitaxel
14	Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder	Completed	NCT00028756	Phase 3	doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
15	A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma	Completed	NCT00942331	Phase 3	Cisplatin;Gemcitabine Hydrochloride
16	Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract	Completed	NCT00315237	Phase 3	vinflunine and best supportive care
17	A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse	Completed	NCT00003701	Phase 3	carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
18	Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder	Completed	NCT00014534	Phase 3	cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
19	Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder	Completed	NCT00003623	Phase 3
20	A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma	Completed	NCT02793128	Phase 3	UGN-101 instillations
21	A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine	Completed	NCT02101931	Phase 3	Amino levulinic Acid
22	A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder	Completed	NCT00330499	Phase 3	Cisplatin
23	A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy	Completed	NCT03410693	Phase 2, Phase 3	Rogaratinib (BAY1163877);Chemotherapy
24	Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy	Completed	NCT00014274	Phase 2, Phase 3	carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
25	A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)	Completed	NCT03374488	Phase 3	Pembrolizumab;Epacadostat;Placebo
26	Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy	Completed	NCT00022191	Phase 3	cisplatin;gemcitabine hydrochloride;paclitaxel
27	Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium	Completed	NCT00003376	Phase 3	carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
28	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy	Completed	NCT02426125	Phase 3	Ramucirumab;Docetaxel;Placebo
29	A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)	Completed	NCT03361865	Phase 3	Pembrolizumab;Epacadostat;Placebo
30	Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study	Completed	NCT02818725	Phase 3	Chemotherapy;Panitumumab
31	A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma	Completed	NCT02853305	Phase 3	Cisplatin;Carboplatin;Gemcitabine
32	Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy	Recruiting	NCT04575935	Phase 3	Chemotherapy
33	Neoadjuvant Chemotherapy in Upper Tract Urothelial Cancer: A Multicentre, Feasibility Pilot Trial	Recruiting	NCT04574960	Phase 3	Gemcitabine;Cisplatin;Carboplatin
34	A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy	Recruiting	NCT04579224	Phase 3	Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel
35	Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)	Recruiting	NCT04637594	Phase 3	Pembrolizumab;Nivolumab;Atezolizumab;Durvalumab;Avelumab
36	A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence	Recruiting	NCT05136898	Phase 3	UGN-102
37	A Randomized Trial Comparing Intravesical Gemcitabine to Continuous Bladder Irrigation With Sterile Water to Prevent Bladder Cancer Implantation in Patients Undergoing Excision of Upper Tract Urothelial Carcinoma	Recruiting	NCT04865939	Phase 3	Gemcitabine
38	A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-Expressing	Recruiting	NCT05302284	Phase 3	RC48-ADC;Toripalimab;Gemcitabine;Cisplatin;Carboplatin
39	A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence	Recruiting	NCT05243550	Phase 3	UGN-102
40	A Phase 3, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma	Recruiting	NCT03967977	Phase 3	Tislelizumab;Placebo;Cisplatin;Gemcitabine Hydrochloride;Carboplatin
41	MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer	Recruiting	NCT05092958	Phase 3	Avelumab;Cabozantinib S-malate
42	A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)	Active, not recruiting	NCT00565851	Phase 3	Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
43	A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy	Active, not recruiting	NCT00108745	Phase 3	Paclitaxel;Paclitaxel Poliglumex
44	A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	NCT02446600	Phase 3	Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
45	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	Active, not recruiting	NCT02502266	Phase 2, Phase 3	Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
46	GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262	Active, not recruiting	NCT01167712	Phase 3	Carboplatin;Paclitaxel
47	A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)	Active, not recruiting	NCT03898180	Phase 3	Lenvatinib;Placebo for lenvatinib
48	S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer	Active, not recruiting	NCT03091660	Phase 3
49	A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (LG IR NMIBC)	Active, not recruiting	NCT04688931	Phase 3	UGN-102
50	Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)	Active, not recruiting	NCT04197986	Phase 3	Infigratinib;Placebo

Search NIH Clinical Center for Transitional Cell Carcinoma

Cochrane evidence based reviews: carcinoma, transitional cell

Sources

Genetic Tests for Transitional Cell Carcinoma

Sources

Anatomical Context for Transitional Cell Carcinoma

Organs/tissues related to Transitional Cell Carcinoma:

MalaCards : Lymph Node, Prostate, Kidney, Lung, Breast, Liver, T Cells

Sources

Publications for Transitional Cell Carcinoma

Articles related to Transitional Cell Carcinoma:

(show top 50) (show all 9616)

#	Title	Authors	PMID	Year
1	Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. ⁵³ ⁶²	Naruse K...Honda N	20428812	2010
2	Sarcomatoid carcinoma of the urinary bladder: a case report with immunohistochemical and molecular genetic analysis. ⁵³ ⁶²	Terada T	19521796	2010
3	Isoenzyme profile of glutathione transferases in transitional cell carcinoma of upper urinary tract. ⁵³ ⁶²	Matic M...Savic-Radojevic A	20403581	2010
4	Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. ⁵³ ⁶²	Petrylak DP...Crawford ED	19888985	2010
5	p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. ⁵³ ⁶²	Kumar B...Koul HK	20068172	2010
6	[Expressions of survivin and the splice variants survivin-2B and survivin-DeltaEx3 in bladder cancer and their clinical significance]. ⁵³ ⁶²	He XF...Cen JN	19895744	2009
7	Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. ⁵³ ⁶²	Simonetti S...Insabato L	19443884	2009
8	Selection of optimal antisense accessible sites of uroplakin II mRNA for bladder urothelium. ⁵³ ⁶²	Zheng L...Dong J	19513619	2009
9	Sulforaphane down-regulates COX-2 expression by activating p38 and inhibiting NF-kappaB-DNA-binding activity in human bladder T24 cells. ⁵³ ⁶²	Shan Y...Bao Y	19287971	2009
10	[Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder]. ⁵³ ⁶²	Song JW...Mi ZG	19615282	2009
11	A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. ⁵³ ⁶²	Boiteux G...Fauconnet S	19115207	2009
12	Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. ⁵³ ⁶²	Atlasi Y...Ziaee SA	19186007	2009
13	Soluble form of carbonic anhydrase IX (CAIX) in transitional cell carcinoma of urinary tract. ⁵³ ⁶²	Hyrsl L...Skapa P	19473055	2009
14	Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study. ⁵³ ⁶²	Salinas-Sanchez AS...Escribano-Martinez J	18367096	2008
15	Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma. ⁵³ ⁶²	Rankin WV...Green JA	19178674	2008
16	Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. ⁵³ ⁶²	Cheng T	18685414	2008
17	DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder. ⁵³ ⁶²	Ma X...Zhang X	18384629	2008
18	p63 expression in ovarian tumours: immunopositivity in metastatic transitional cell carcinoma of the ovary. ⁵³ ⁶²	Kalebi A...Hale M	18518899	2008
19	Insights from a whole cystectomy specimen--association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ. ⁵³ ⁶²	Gaisa NT...Knuchel R	18547617	2008
20	RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. ⁵³ ⁶²	Wolff EM...Jones PA	18676844	2008
21	The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. ⁵³ ⁶²	Klatte T...Pantuck AJ	18430124	2008
22	Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. ⁵³ ⁶²	Shang D...Ogawa O	18538698	2008
23	Differential accumulation of hypericin in spheroids composed of T-24 transitional cell carcinoma cells expressing different levels of E-cadherin. ⁵³ ⁶²	Huygens A...de Witte PA	18355860	2008
24	SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. ⁵³ ⁶²	Hsu LI...Chen CJ	18199464	2008
25	Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. ⁵³ ⁶²	Hammam OA...Abdel Hadi AM	18449376	2008
26	Survivin: a promising biomarker for detection and prognosis of bladder cancer. ⁵³ ⁶²	Margulis V...Shariat SF	17962949	2008
27	Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. ⁵³ ⁶²	Moussa O...Watson DK	17603559	2008
28	Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. ⁵³ ⁶²	Liu L...Guo H	18645275	2008
29	Downregulation of survivin is associated with reductions in TNF receptors' mRNA and protein and alterations in nuclear factor kappa B signaling in urothelial cancer cells. ⁵³ ⁶²	Takizawa BT...Weiss RM	18058462	2007
30	Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells. ⁵³ ⁶²	Kuncova J...Mandys V	18092951	2007
31	Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma. ⁵³ ⁶²	Lee JY...Inokuma H	17316722	2007
32	The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. ⁵³ ⁶²	Kim J...Freeman MR	17909029	2007
33	Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. ⁵³ ⁶²	Baccala A...Zhou M	17826525	2007
34	Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway. ⁵³ ⁶²	Zhang G...See WA	17483019	2007
35	Cyclooxygenase-2 in transitional cell carcinoma--a legitimate target? ⁵³ ⁶²	Adam R	17296349	2007
36	Expression of p63 in thymomas and normal thymus. ⁵³ ⁶²	Dotto J...Rosai J	17276940	2007
37	Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. ⁵³ ⁶²	Margulis V...Lotan Y	17296438	2007
38	Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. ⁵³ ⁶²	Esuvaranathan K...Teh M	17311305	2007
39	Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. ⁵³ ⁶²	Shariat SF...Lotan Y	17222615	2007
40	Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. ⁵³ ⁶²	Dalbagni G...Reuter VE	17155984	2007
41	EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. ⁵³ ⁶²	Hinz S...Christoph F	17541304	2007
42	P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification. ⁵³ ⁶²	Kalantari MR...Ahmadnia H	18270948	2007
43	Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. ⁵³ ⁶²	Jalali Nadoushan MR...Zaeri F	17987577	2007
44	Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. ⁵³ ⁶²	Christoph F...Schrader M	16473461	2007
45	Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. ⁵³ ⁶²	Christoph F...Schrader M	17133271	2006
46	Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. ⁵³ ⁶²	Shariat SF...Lotan Y	16949911	2006
47	Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. ⁵³ ⁶²	Maluf FC...Bajorin DF	16984978	2006
48	Overexpression of PAX5 in oral carcinogenesis. ⁵³ ⁶²	Norhany S...Tanzawa H	17016584	2006
49	The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. ⁵³ ⁶²	Hilmy M...McMillan DC	17024120	2006
50	The role of glutathione transferases M1 and T1 in individual susceptibility to bladder cancer in a Tunisian population. ⁵³ ⁶²	Ouerhani S...Elgaaied AB	17381051	2006

Sources

Genes for Transitional Cell Carcinoma

Genes related to Transitional Cell Carcinoma (0 elite genes):

(show top 50) (show all 59)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	UPK2	Uroplakin 2	Protein Coding	32.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	9846985 10458411 19513619 (more) 12474225 12792753
2	UPK1A	Uroplakin 1A	Protein Coding	28.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	12474225
3	TP53	Tumor Protein P53	Protein Coding	25.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15825690 7796648 8217593 (more) 9720535 10210109 10872039 1712624 9817315 10675477 9275651 10736495 10782026 18547617 17155984 17222615 8012775 9179692 16351648 12926093 11836589 9649138 9477105 9466048 8689624 11286838 11168685 10629648 9816132 7658499 8078807 16825812 15183954 11310375 9644783 7785554 16328005 15386300 9240594 18092951 11223675 11127510 9821049 8778319 8402668 18367096 18645275 12908522 9264274 9037278 8012776 7713133 9514058 9852285 10895017 11306883 10371737 9338472 9186361 9111623 8934528 7537927 8001930 17311305 9392055 12544295 12380307 11025381 10869658 10675480 10492244 10672952 9759996 9426716 16984978 10208458 10668937 9614448 9079754 8633392 7850321 8015113 7511288 18270948 16903935 16126329 9286659 7715016 7511289 17483019 14575574 12725329 12684626 12607601 11806441 11669339 11161387 10919661 10872671 10804290
4	KRT20	Keratin 20	Protein Coding	23.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9817302 11490230 9067104 (more) 11693559 10893639 16140073 12502922 16473461 8835265 11696722 15245962 15017198 19521796 10765100 12172048 19300416
5	UPK3A	Uroplakin 3A	Protein Coding	23.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12502922 12474225 7511294
6	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	22.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1361954 1712624 12474525 (more) 15667899 19443884 1673627 8094432 9477105 17987577 7785554 11342901 14687790 8099896 8539234 1978950 7713133 10792078 15581965 14520464 7915094 15351620 15072912 7509541 1364264 15879779 11295084 20428812 1358427 16466848 1942310 16469569 14614020 7827848 8001930 15870865
7	KRT7	Keratin 7	Protein Coding	21.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11190802 8685046 1690512 (more) 19050800
8	UPK1B	Uroplakin 1B	Protein Coding	21.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9846985 9818021 12474225
9	CDH1	Cadherin 1	Protein Coding	21.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11555602 18384629 7533658 (more) 15967254 7538603 11342899 10070307 9783980 11839665 14728827 16799706 18355860 12395372 10210565 16142373 18676844 16126329 14575574 7672793 10388228 10523852
10	EGFR	Epidermal Growth Factor Receptor	Protein Coding	21.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1361954 1868471 9477105 (more) 8539234 7906919 1712624 9240594 1690599 9586623 8365434 10974634 7936759 19888985 11342901 9521509 10998445 10037173 8538164 15082004 17909029 7827848 15892828 1694766 7819039 9815668
11	BRINP1	BMP/Retinoic Acid Inducible Neural Specific 1	Protein Coding	20.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11921286
12	UBIAD1	UbiA Prenyltransferase Domain Containing 1	Protein Coding	20.68	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Proteins (show sections)
13	MKI67	Marker Of Proliferation Ki-67	Protein Coding	20.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7936759 7824516 14517702 (more) 10940702 9392055 11286838 9490274 9521509 1538273 8459037 11161387 16351648 16126329 7511288
14	IFNA2	Interferon Alpha 2	Protein Coding	18.74	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8535711 9883220 1835608 (more) 9037279 8278878 7639570 8348503 8976220 1611117 7981084 15592090 1611118 12017377 1924449 8499986 9192993 12518191
15	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	18.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12576817 17296438 17024120 (more) 10582676 10873095 15450303 11238034 12913755 12949405 12429306 12614262 16401921 15870865 16132759 18449376 19287971 15592025 11443626 20428812 12269772 18676844 17296349 17316722 11297248 11827414 11809678 12470662
16	PSCA	Prostate Stem Cell Antigen	Protein Coding	18.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12771726 16686711 11406532
17	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	18.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11314002 15701828 11745189
18	TP63	Tumor Protein P63	Protein Coding	18.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15183954 11839669 17880529 (more) 12871991 18518899 17276940 15237589
19	MSH2	MutS Homolog 2	Protein Coding	18.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16126329 12650804 15922421 (more) 15235034
20	KRT18	Keratin 18	Protein Coding	18.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19615282 12629348 1694766 (more) 10850364 11913716
21	MDM2	MDM2 Proto-Oncogene	Protein Coding	18.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11836589 12908522 11168685 (more) 7537927 9521509 11488730 16984978 9186361
22	MMP9	Matrix Metallopeptidase 9	Protein Coding	18.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12670552 11342973 16351648 (more) 11555602 20068172 16901349 10081908 9865914 15028476
23	BIRC5	Baculoviral IAP Repeat Containing 5	Protein Coding	18.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15730809 12461612 18685414 (more) 17559031 16126329 19186007 18058462 17962949 17603559 16635519 12796695 14713775 19178674 19895744
24	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	17.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8740026 10550296 10022688 (more) 7533658 9228671 9602328 11693559 14981907 15783086 7538603
25	ENO2	Enolase 2	Protein Coding	17.82	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2313795 8099896
26	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	17.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17222615 17483019 16949911 (more) 10804290 11488730 14981105 15590562 11127920 10872671 11161387
27	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	17.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17138155 17541304 16361539
28	MLH1	MutL Homolog 1	Protein Coding	17.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11342971 12509916 15963139
29	KRT19	Keratin 19	Protein Coding	17.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9224298
30	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	17.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10397466 18199464 15548945 (more) 17381051
31	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	17.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14614020 8869284
32	DAPK1	Death Associated Protein Kinase 1	Protein Coding	17.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11839665 18676844 16642478 (more) 17133271
33	KLK3	Kallikrein Related Peptidase 3	Protein Coding	16.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8638540 9222310 12894737 (more) 9879288 1713065 15471072
34	GSTP1	Glutathione S-Transferase Pi 1	Protein Coding	16.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20403581 11839665 8281406 (more) 8791059 11061940
35	ERBB4	Erb-B2 Receptor Tyrosine Kinase 4	Protein Coding	16.47	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14614020
36	PLAUR	Plasminogen Activator, Urokinase Receptor	Protein Coding	16.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15191676 14981816 15375521 (more) 12736046 15783118 9477106 14634389
37	PLAU	Plasminogen Activator, Urokinase	Protein Coding	16.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14981816 15191676 15375521 (more) 14644129 9477106 12736046 14634389
38	CA9	Carbonic Anhydrase 9	Protein Coding	16.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19473055 15069539 18430124
39	EPHB2	EPH Receptor B2	Protein Coding	16.15	GeneCards inferred via : Disorders Publications (show sections)
40	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	16.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10530564 10666370 12509916
41	FABP4	Fatty Acid Binding Protein 4	Protein Coding	15.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19115207
42	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	15.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9891471 8535713 8735718 (more) 11115597 8813946 8859190 15088897
43	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	15.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19050800
44	THBD	Thrombomodulin	Protein Coding	15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9447382 9728615 12502922 (more) 10368666
45	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	14.98	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9392054 9179692 8093979 (more) 7824516 7936759 10468892 8653317 9392055 9463280 1349799 11342901 9645444 9521509 9477184 9187909 9585059 8859190 8854073 1361436 9614448 9079742 7511289 7910097 9252716 15814637 7511288
46	APAF1	Apoptotic Peptidase Activating Factor 1	Protein Coding	14.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17541304 16642478 17133271
47	BSG	Basigin (Ok Blood Group)	Protein Coding	14.88	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16633062 18685414
48	MCM2	Minichromosome Maintenance Complex Component 2	Protein Coding	14.88	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12565771 11948116
49	AMFR	Autocrine Motility Factor Receptor	Protein Coding	14.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7490884 14685796
50	DNMT1	DNA Methyltransferase 1	Protein Coding	14.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14634451 12594811 18538698

Sources

Variations for Transitional Cell Carcinoma

Copy number variations for Transitional Cell Carcinoma from CNVD:

⁶ (show top 50) (show all 92)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	26136	1	197500000	205300000	Amplification	LRRN2	Urothelial cell carcinoma
2	26141	1	197500000	205300000	Amplification	MDM4	Urothelial cell carcinoma
3	26154	1	197500000	205300000	Loss		Urothelial cell carcinoma
4	42679	10	3800000	6700000	Amplification	PFKFB3	Urothelial cell carcinoma
5	49670	11	110000000	115400000	Loss	ANKK1	Urothelial cell carcinoma
6	49671	11	110000000	115400000	Loss	DRD2	Urothelial cell carcinoma
7	49672	11	110000000	115400000	Loss	NCAM1	Urothelial cell carcinoma
8	49673	11	110000000	115400000	Loss	TTC12	Urothelial cell carcinoma
9	52333	11	16100000	21600000	Loss	PLEKHA7	Urothelial cell carcinoma
10	58688	11	69200000	70700000	Amplification	CCND1	Urothelial cell carcinoma
11	58689	11	69200000	70700000	Amplification	FGF19	Urothelial cell carcinoma
12	58690	11	69200000	70700000	Amplification	FGF3	Urothelial cell carcinoma
13	58692	11	69200000	70700000	Amplification	FGF4	Urothelial cell carcinoma
14	58694	11	69200000	70700000	Amplification	LTO1	Urothelial cell carcinoma
15	58695	11	69200000	70700000	Amplification	TPCN2	Urothelial cell carcinoma
16	58889	11	70700000	74900000	Amplification		Urothelial cell carcinoma
17	58890	11	70700000	74900000	Amplification	SHANK2-AS3	Urothelial cell carcinoma
18	58891	11	70700000	74900000	Amplification	SHANK2	Urothelial cell carcinoma
19	64483	12	128700000	132349534	Loss	FZD10	Urothelial cell carcinoma
20	69470	12	55200000	56300000	Amplification	ARHGAP9	Urothelial cell carcinoma
21	69471	12	55200000	56300000	Amplification	DCTN2	Urothelial cell carcinoma
22	69472	12	55200000	56300000	Amplification	GLI1	Urothelial cell carcinoma
23	69473	12	55200000	56300000	Amplification	INHBC	Urothelial cell carcinoma
24	69474	12	55200000	56300000	Amplification	KIF5A	Urothelial cell carcinoma
25	69475	12	55200000	61400000	Amplification	CDK4	Urothelial cell carcinoma
26	69476	12	55200000	61400000	Amplification	METTL1	Urothelial cell carcinoma
27	69477	12	55200000	61400000	Amplification	TSFM	Urothelial cell carcinoma
28	69795	12	56300000	61400000	Amplification	TAFA2	Urothelial cell carcinoma
29	69796	12	56300000	61400000	Amplification	SLC16A7	Urothelial cell carcinoma
30	70900	12	66000000	69800000	Amplification	CNOT2	Urothelial cell carcinoma
31	70901	12	66000000	69800000	Amplification	CPM	Urothelial cell carcinoma
32	70902	12	66000000	69800000	Amplification	IFNG	Urothelial cell carcinoma
33	70903	12	66000000	69800000	Amplification	IL22	Urothelial cell carcinoma
34	70904	12	66000000	69800000	Amplification	IL26	Urothelial cell carcinoma
35	70910	12	66000000	69800000	Amplification	MDM2	Urothelial cell carcinoma
36	70911	12	66000000	69800000	Amplification	TSPAN8	Urothelial cell carcinoma
37	71411	12	69800000	74100000	Amplification	LGR5	Urothelial cell carcinoma
38	71412	12	69800000	74100000	Amplification	THAP2	Urothelial cell carcinoma
39	71413	12	69800000	74100000	Amplification	TMEM19	Urothelial cell carcinoma
40	71414	12	69800000	74100000	Amplification	TPH2	Urothelial cell carcinoma
41	71668	12	74100000	78700000	Amplification	NAV3	Urothelial cell carcinoma
42	72907	12	87500000	91200000	Amplification	KITLG	Urothelial cell carcinoma
43	73109	12	91200000	94800000	Amplification	PLXNC1	Urothelial cell carcinoma
44	79797	13	77800000	86500000	Loss		Urothelial cell carcinoma
45	94764	15	70400000	73100000	Loss	NPTN	Urothelial cell carcinoma
46	109762	17	28800000	35600000	Amplification	ERBB2	Urothelial cell carcinoma
47	109763	17	28800000	35600000	Amplification	TCAP	Urothelial cell carcinoma
48	123109	18	66900000	71300000	Loss		Urothelial cell carcinoma
49	123110	18	66900000	71300000	Loss	TSHZ1	Urothelial cell carcinoma
50	123111	18	66900000	71300000	Loss	PTGR3	Urothelial cell carcinoma

Sources

Expression for Transitional Cell Carcinoma

Search GEO for disease gene expression data for Transitional Cell Carcinoma.

Sources

Pathways for Transitional Cell Carcinoma

Pathways related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)

#	Super pathways	Score	Top Affiliating Genes
1	DNA Damage ³	12.35	TP63 TP53 MSH2 MKI67
2	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.32	TP53 PTGS2 MSH2 FGFR3 ERBB2 EGFR
3	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.29	TP53 PTGS2 ERBB2 CDH1
4	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.28	TP53 FGFR3 ERBB2 EGFR
5	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.26	TP53 ERBB2 EGFR CDH1
6	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.25	TP53 FGFR3 ERBB2 EGFR
7	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.05	TP53 FGFR3 ERBB2 EGFR
8	Integrated breast cancer pathway ⁷⁴	11.91	CDH1 EGFR MSH2 TP53
9	Colorectal Cancer Metastasis ⁶⁴	11.87	TP53 PTGS2 MSH2 EGFR CDH1
10	mTOR Signaling ⁶⁵	11.85	TP53 FGFR3 ERBB2 EGFR
11	Direct p53 effectors ⁶¹	11.73	TP63 TP53 MSH2 EGFR
12	Burn wound healing ⁷⁴	11.55	TP53 IFNA2 FGFR3
13	Alzheimers Disease Pathway ⁶⁴	11.29	FGFR3 ERBB2 EGFR
14	Head and neck squamous cell carcinoma ⁷⁴	11.22	TP63 TP53 FGFR3 ERBB2 EGFR
15	a6b1 and a6b4 Integrin signaling ⁶¹	11.11	ERBB2 EGFR CDH1
16	Bladder cancer ⁷⁴	10.7	UPK3A TP53 FGFR3 ERBB2 EGFR CDH1
17	Relationship between inflammation, COX-2 and EGFR ⁷⁴	10.52	PTGS2 EGFR
18	Mammary gland development pathway - Involution (Stage 4 of 4) ⁷⁴	10.51	TP53 CDH1

Sources

GO Terms for Transitional Cell Carcinoma

Cellular components related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	apical plasma membrane urothelial plaque	GO:0120001	9.1	UPK3A UPK1B UPK1A

Biological processes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	GO:0042771	9.43	TP63 TP53 MSH2
2	epithelial cell differentiation	GO:0030855	9.36	UPK3A UPK2 UPK1B UPK1A TP63 KRT20
3	positive regulation of miRNA maturation	GO:1903800	9.16	TP53 EGFR